Publicação
Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects
| Resumo: | Objective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat. Methods: ZDF rats (aged 20 weeks) were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia, HbA1c, urea and creatinine levels were monitored. Kidney glomerular and tubulointerstitial lesions were assessed using a semiquantitative rating. Kidney mRNA and/or protein content of DPP-IV, GLP-1, TNF-α, IL-1β, BAX, Bcl-2 and Bid were evaluated by RT-PCR and/or WB. Protein distribution was evaluated by immunohistochemistry. Results: Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c, and prevented the diabetes-induced increase in DPP-IV levels and decrease in GLP-1 levels. Sitagliptin ameliorated diabetes-induced glomerular atrophy and IFTA, and the increased urea levels. Sitagliptin decreased kidney IL-1β and TNF-α, and prevented the increase of BAX/Bcl-2 ratio and Bid protein levels, which indicates protective effects against inflammation and pro-apoptotic state in the kidney of diabetic rats, respectively. Conclusion: Sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and anti-apoptotic properties. |
|---|---|
| Autores principais: | Marques, C. |
| Outros Autores: | Mega, C.; Gonçalves, A.; Rodrigues-Santos, P.; Vala, Helena; Teixeira-Lemos, E.; Teixeira, F.; Fontes-Ribeiro, C.; Reis, F.; Fernandes, R. |
| Assunto: | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| Ano: | 2014 |
| País: | Portugal |
| Tipo de documento: | documento de conferência |
| Tipo de acesso: | acesso restrito |
| Instituição associada: | Instituto Politécnico de Viseu |
| Idioma: | inglês |
| Origem: | Repositório Científico do Instituto Politécnico de Viseu |
| _version_ | 1863854293181792256 |
|---|---|
| author | Marques, C. |
| author2 | Mega, C. Gonçalves, A. Rodrigues-Santos, P. Vala, Helena Teixeira-Lemos, E. Teixeira, F. Fontes-Ribeiro, C. Reis, F. Fernandes, R. |
| author2_role | author author author author author author author author author |
| author_facet | Marques, C. Mega, C. Gonçalves, A. Rodrigues-Santos, P. Vala, Helena Teixeira-Lemos, E. Teixeira, F. Fontes-Ribeiro, C. Reis, F. Fernandes, R. |
| author_role | author |
| contributor_name_str_mv | Instituto Politécnico de Viseu |
| country_str | PT |
| creators_json_str | [{\"Person.name\":\"Marques, C.\"},{\"Person.name\":\"Mega, C.\"},{\"Person.name\":\"Gonçalves, A.\"},{\"Person.name\":\"Rodrigues-Santos, P.\"},{\"Person.name\":\"Vala, Helena\",\"Person.identifier.orcid\":\"0000-0001-6829-4867\"},{\"Person.name\":\"Teixeira-Lemos, E.\"},{\"Person.name\":\"Teixeira, F.\"},{\"Person.name\":\"Fontes-Ribeiro, C.\"},{\"Person.name\":\"Reis, F.\"},{\"Person.name\":\"Fernandes, R.\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | Instituto Politécnico de Viseu |
| datacite.creators.creator.creatorName.fl_str_mv | Marques, C. Mega, C. Gonçalves, A. Rodrigues-Santos, P. Vala, Helena Teixeira-Lemos, E. Teixeira, F. Fontes-Ribeiro, C. Reis, F. Fernandes, R. |
| datacite.date.Accepted.fl_str_mv | 2014-01-01T00:00:00Z |
| datacite.date.available.fl_str_mv | 2015-03-23T10:08:22Z |
| datacite.date.embargoed.fl_str_mv | 2015-03-23T10:08:22Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_16ec |
| datacite.subjects.subject.fl_str_mv | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| datacite.titles.title.fl_str_mv | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| dc.contributor.none.fl_str_mv | Instituto Politécnico de Viseu |
| dc.creator.none.fl_str_mv | Marques, C. Mega, C. Gonçalves, A. Rodrigues-Santos, P. Vala, Helena Teixeira-Lemos, E. Teixeira, F. Fontes-Ribeiro, C. Reis, F. Fernandes, R. |
| dc.date.Accepted.fl_str_mv | 2014-01-01T00:00:00Z |
| dc.date.available.fl_str_mv | 2015-03-23T10:08:22Z |
| dc.date.embargoed.fl_str_mv | 2015-03-23T10:08:22Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10400.19/2715 |
| dc.language.none.fl_str_mv | eng |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_16ec |
| dc.subject.none.fl_str_mv | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| dc.title.fl_str_mv | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_c94f |
| description | Objective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat. Methods: ZDF rats (aged 20 weeks) were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia, HbA1c, urea and creatinine levels were monitored. Kidney glomerular and tubulointerstitial lesions were assessed using a semiquantitative rating. Kidney mRNA and/or protein content of DPP-IV, GLP-1, TNF-α, IL-1β, BAX, Bcl-2 and Bid were evaluated by RT-PCR and/or WB. Protein distribution was evaluated by immunohistochemistry. Results: Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c, and prevented the diabetes-induced increase in DPP-IV levels and decrease in GLP-1 levels. Sitagliptin ameliorated diabetes-induced glomerular atrophy and IFTA, and the increased urea levels. Sitagliptin decreased kidney IL-1β and TNF-α, and prevented the increase of BAX/Bcl-2 ratio and Bid protein levels, which indicates protective effects against inflammation and pro-apoptotic state in the kidney of diabetic rats, respectively. Conclusion: Sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and anti-apoptotic properties. |
| dirty | 0 |
| eu_rights_str_mv | restrictedAccess |
| format | conferenceObject |
| fulltext.url.fl_str_mv | https://repositorio.ipv.pt/bitstreams/89582d94-8dbd-4812-9dd9-707367b1c7c6/download |
| id | ripv_ee4bc9e6a3bfe8a85509dba98ac8a93a |
| identifier.url.fl_str_mv | http://hdl.handle.net/10400.19/2715 |
| instacron_str | ripv |
| institution | Instituto Politécnico de Viseu |
| instname_str | Instituto Politécnico de Viseu |
| language | eng |
| network_acronym_str | ripv |
| network_name_str | Repositório Científico do Instituto Politécnico de Viseu |
| oai_identifier_str | oai:repositorio.ipv.pt:10400.19/2715 |
| organization_str_mv | urn:organizationAcronym:ripv |
| person_str_mv | Marques, C. Mega, C. Gonçalves, A. Rodrigues-Santos, P. Vala, Helena Vala, Helena https://www.ciencia-id.pt/7A1E-E85E-FFA4 7A1E-E85E-FFA4 http://orcid.org/0000-0001-6829-4867 0000-0001-6829-4867 Teixeira-Lemos, E. Teixeira, F. Fontes-Ribeiro, C. Reis, F. Fernandes, R. |
| publishDate | 2014 |
| reponame_str | Repositório Científico do Instituto Politécnico de Viseu |
| repository_id_str | urn:repositoryAcronym:ripv |
| service_str_mv | urn:repositoryAcronym:ripv |
| spelling | engporObjective: This study aimed to evaluate the efficacy of sitagliptin, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in preventing the deleterious effects of diabetes on the kidney in an animal model of T2DM, the Zucker Diabetic Fatty (ZDF) rat. Methods: ZDF rats (aged 20 weeks) were treated with sitagliptin (10 mg/kg bw/day) during 6 weeks. Glycaemia, HbA1c, urea and creatinine levels were monitored. Kidney glomerular and tubulointerstitial lesions were assessed using a semiquantitative rating. Kidney mRNA and/or protein content of DPP-IV, GLP-1, TNF-α, IL-1β, BAX, Bcl-2 and Bid were evaluated by RT-PCR and/or WB. Protein distribution was evaluated by immunohistochemistry. Results: Sitagliptin treatment improved glycaemic control, as reflected by the significantly reduced levels of glycaemia and HbA1c, and prevented the diabetes-induced increase in DPP-IV levels and decrease in GLP-1 levels. Sitagliptin ameliorated diabetes-induced glomerular atrophy and IFTA, and the increased urea levels. Sitagliptin decreased kidney IL-1β and TNF-α, and prevented the increase of BAX/Bcl-2 ratio and Bid protein levels, which indicates protective effects against inflammation and pro-apoptotic state in the kidney of diabetic rats, respectively. Conclusion: Sitagliptin might have a major role in preventing diabetic nephropathy evolution due to anti-inflammatory and anti-apoptotic properties.application/pdfporSitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effectsMarques, C.Mega, C.Gonçalves, A.Rodrigues-Santos, P.PersonalVala, HelenaDSpacehttp://dspace.org/items/cdc3d2e2-df06-40ed-8900-1ecbc8a06c8aDSpacehttp://dspace.org/items/cdc3d2e2-df06-40ed-8900-1ecbc8a06c8aVala CorreiaHelena MariaCiência IDhttps://www.ciencia-id.pt7A1E-E85E-FFA4ORCIDhttp://orcid.org0000-0001-6829-4867Teixeira-Lemos, E.Teixeira, F.Fontes-Ribeiro, C.Reis, F.Fernandes, R.HostingInstitutionOrganizationalInstituto Politécnico de Viseue-mailmailto:repositorio@sc.ipv.ptrepositorio@sc.ipv.pt2015-03-23T10:08:22Z20142014-01-01T00:00:00ZHandlehttp://hdl.handle.net/10400.19/2715http://purl.org/coar/access_right/c_16ecrestricted accesssitagliptinZucker Diabetic Fatty (ZDF) ratanimal model of T2DMdipeptidyl peptidase IV (DPP-IV) inhibitor1729316 bytesother research producthttp://purl.org/coar/resource_type/c_c94fconference objecthttp://purl.org/coar/access_right/c_16ecapplication/pdffulltexthttps://repositorio.ipv.pt/bitstreams/89582d94-8dbd-4812-9dd9-707367b1c7c6/downloadVirchows Arch465 (Supll I) |
| spellingShingle | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects Marques, C. sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| subject.fl_str_mv | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| title | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| title_full | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| title_fullStr | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| title_full_unstemmed | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| title_short | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| title_sort | Sitagliptin ameliorates kidney lesions in a rat model of type 2 diabetes due to anti-inflammatory and anti-apoptotic effects |
| topic | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| topic_facet | sitagliptin Zucker Diabetic Fatty (ZDF) rat animal model of T2DM dipeptidyl peptidase IV (DPP-IV) inhibitor |
| url | http://hdl.handle.net/10400.19/2715 |
| visible | 1 |